Ahmed Khalid, MD
Hematology & Oncology · Charleston, WVNPI 1649234121
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,665 of the $8,275 with a category attached, or 68.5%. Novartis accounts for 67.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $5,557 and has fallen 92.9% since, to $395 in 2025.
Across 47 payments — averaging $176.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- Beigene USA, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$294
- Boston Scientific$168
- Genentech USA, Inc.$133
- Getinge USA Sales, LLC$115
- plus $301 from 9 others
Across 2 payments — averaging $1112.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2K
What the payments were for
- Consulting fees$5,66568%
- Travel & lodging$1,20415%
- Food & beverage$1,38817%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $5,619 |
| Beigene USA, Inc. | 2 | $1,645 |
| E.r. Squibb & Sons, L.L.C. | 8 | $294 |
| Boston Scientific | 2 | $168 |
| Genentech USA, Inc. | 1 | $133 |
| Getinge USA Sales, LLC | 2 | $115 |
| Regeneron Healthcare Solutions, Inc. | 4 | $87 |
| Johnson & Johnson(2 entities) | 3 | $57 |
| AbbVie | 2 | $43 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Gilead(2 entities) | 2 | $26 |
| GSK | 1 | $17 |
| Pfizer | 1 | $16 |
| Bristol Myers Squibb | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,275 in reported general payments places this provider in the 80th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 62 | $864,391 |
| ImbruvicaIbrutinib | 55 | $854,406 |
| IbrancePalbociclib | 41 | $666,269 |
| RevlimidLenalidomide | 35 | $582,244 |
| VerzenioAbemaciclib | 31 | $484,809 |
| KisqaliRibociclib Succinate | 30 | $450,489 |
| OnuregAzacitidine | 13 | $337,650 |
| CabometyxCabozantinib S-Malate | 12 | $271,527 |
| TasignaNilotinib Hcl | 12 | $226,068 |
| XtandiEnzalutamide | 15 | $193,303 |
| BrukinsaZanubrutinib | 20 | $186,379 |
| NinlaroIxazomib Citrate | 11 | $143,436 |
| NubeqaDarolutamide | 13 | $89,994 |
| VenclextaVenetoclax | 12 | $64,326 |
| EliquisApixaban | 81 | $63,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $16 | $729,888122 claims |
| NovartisKisqali, Tasigna | $5,619 | $676,55742 claims |
| Bristol Myers SquibbRevlimid | $14 | $582,24435 claims |
| E.r. Squibb & Sons, L.L.C.Onureg | $294 | $337,65013 claims |
| Beigene USA, Inc.Brukinsa | $1,645 | $186,37920 claims |
| AbbVieVenclexta | $43 | $64,32612 claims |
| Johnson & JohnsonXarelto | $57 | $45,95033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Charleston
- Pranali PachikaCharleston$9K
- Mohammad Ahsan AlamgirCharleston$9K
- Nagabhishek MokaCharleston$8K
- Moussa SissokoCharleston$5K
- Kok Hoe ChanCharleston$2K
- Muhammad AwidiCharleston$559
- Chitta SarkerCharleston$304
- Steven JubelirerCharleston$253
- Damian SilberminsHuntington$277K
- Abraham KanateMorgantown$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.